Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
NCT06058234
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mild Alzheimer's Disease
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- Any age
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
- Last updated on ClinicalTrials.gov
- September 28, 2023
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Centers for Medicare and Medicaid Services · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.